ClinicalTrials.gov
public full text
Public Domain
Sitagliptin and Endothelial Dysfunction
Over the years, numbers of cardioprotective drugs have been evaluated to attenuate lethal ischemia-reperfusion (IR) injuries. There is little study whether sitagliptin protects against endothelial dysfunction induced by IR injury in humans.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Natural compounds targeting inflammatory signaling and cell adhesion molecules in ischemic acute kidney injury.#247565
- Therapeutic intervention with sinomenine and irisin to preserve cardiac function after ischaemia-reperfusion injury.#396087
- The pathophysiology of acute myocardial infarction and strategies of protection beyond reperfusion: a continual challenge#400203
- Predictive Study of Serum Endocan for Hemorrhagic Transformation After Reperfusion Therapies in Acute Ischemic Stroke#845686
- A Randomized, Double-blind Study of the Effects of Fenretinide Administered in Subjects With Obesity#1102656
Record · ID 813812
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive